Funding for this research was provided by:
Eli Lilly and Company
Received: 18 May 2023
Accepted: 13 June 2023
First Online: 4 August 2023
: This study was conducted in accordance with the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical Guidelines, International Conference on Harmonisation guidelines for Good Clinical Practice, and applicable local laws and regulations. Patients provided written informed consent before undergoing any study procedures. The appropriate institutional review board for each participating site approved the study protocol, patient consent form and other relevant documents.
: Not applicable.
: LS, HL and CQ are full-time employees of Eli Lily and Company. SY serves as associated editor of the Journal of Headache and Pain and as a member of the International Headache Society. MZ has no competing interests. JZ, LZ, DC, KS, GL, XY and SY declare receiving clinical research fees from Eli Lilly and Company for participating as investigators in the PERSIST study.